PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem
Published: 25 October 2021
-
Views:
8619 -
Likes:
7
-
Views:
8619 -
Likes:
7
-
3m 28s
-
19m 12sPart 6 | Session 2 Prof Joško Bulum presents his experience with the iVAC 2L
-
34m 9sPart 1 PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in clinical practice Nicolas M Van Mieghem
-
26sPart 2 | Session 1 Introduction Nicolas M Van Mieghem
-
4m 29sPart 2 | Session 2 MCS indications and patient selection Nicolas M Van Mieghem
-
4m 10sPart 2 | Session 3 Overview: Percutaneous MCS Systems Nicolas M Van Mieghem
-
3m 44sPart 2 | Session 4 Key Findings: Clinical Experience high-risk PCI next generation MCS protected in Erasmus MC Nicolas M Van Mieghem
-
2m 50sPart 2 | Session 5 Patient screening and access site management Nicolas M Van Mieghem
-
4m 9sPart 2 | Session 6 iVAC 2L ® technology overview, procedure, technique and performance Nicolas M Van Mieghem
-
3m 6sPart 2 | Session 7 Summary: iVAC 2L ® and Mechanical Unloading Nicolas M Van Mieghem
-
5m 5sPart 2 | Session 8 Study Design and Population Nicolas M Van Mieghem
-
3m 45sPart 2 | Session 9 Key Findings Nicolas M Van Mieghem
-
1m 18sPart 2 | Session 10 iVAC 2L ® effects on Cardiac Mechanics Nicolas M Van Mieghem
-
1m 10sPart 2 | Session 11 Pulse Trial Conclusion Nicolas M Van Mieghem
-
4m 57sPart 2 | Session 12 Frequently Asked Questions Nicolas M Van Mieghem
-
2m 18sPart 3 iVAC 2L ® - pVAD
-
18m 41sPart 4 | Session 1 Pulsatile LV support during high-risk PCI (the PulseCath iVAC 2L) Joost Daemen
-
10m 6sPart 4 | Session 2 The concept of pulsatile LV support (the PulseCath iVAC 2L) Joost Daemen
-
9m 48sPart 4 | Session 3 Pulsatile vs. Continuous percutaneous MCS Joost Daemen
Overview
In this video series, Professor Nicolas van Mieghem will discuss the benefits of iVAC 2L ® in clinical practice and will share the learnings and key outcomes from the Pulse Trial, and the effect of next generation pulsatile mechanical circulatory support (MCS).
This video is supported by PulseCath in collaboration with their co-sponsors: CardiRad, Sanomed, LeviBio, Thomy F.E., Sonimed and Dot Medical.
Key Learning Objectives
- Learn when to use the short term percutaneous ventricular assist device (pVAD), iVAC 2L ® in clinical practice
- Understand the differences between pulsatile and continuous flow
- Understand the technology behind the device
- Gain a better understanding of how the iVAC 2L ® is more efficient
- Learn how to identify the right patient (HR PCI)
- Learn when to use iVAC 2L ® vs Impella
- Further understanding of large bore access management
Target Audience
- Interventional Cardiologists
- Cardiac Surgeons
- Cardiac Nurses
- Cath Lab Nurses
- ICU Doctors
- Perfusionists
- Cath Lab Technicians
More from this programme
Part 1
Full Programme - PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem
Part 2
Chapters of Programme - PULSE-trial: Summarising the Clinical Outcomes and Benefits of iVAC 2L ® in Clinical Practice: An Expert Discussion with Prof Nicolas van Mieghem
Part 3
iVAC 2L ® - pVAD procedure
1 session | |
iVAC 2L ® - pVAD | Watch now |
Part 4
Pulsatile LV support during high-risk PCI
Part 5
iVAC 2L experience from CINRE hospital – Bratislava - Slovakia
Part 6
iVAC 2L experience from University Hospital Centre Zagreb, Zagreb, HR
Part 7
Procedure IVAC 2L in high risk PCI University Hospital of Bellvitge, Barcelona, (Spanish)
Dr Joan Antoni Gomez-Hospital (University Hospital of Bellvitge, Barcelona, ES) shares his experience on the iVAC 2L and the practical issues.
Part 8
iVAC 2L experience from University Hospital of Bellvitge, Barcelona, ES
Faculty Biographies
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.